Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
EHA 2025 – J&J claims an extramedullary edge
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.
ASCO 2025 – J&J challenges its own multiple myeloma T-cell engagers
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Galapagos split stutters
The group’s point-of-care Car-T push looks to have stalled.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
